Madrigal Pharmaceuticals said on Wednesday it has entered into a licensing agreement worth up to $2 billion with China's CSPC Pharmaceutical Group to develop an oral GLP-1 drug for a serious form of ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's nonprofit acquires 23andMe.

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

HANGZHOU (Reuters) -China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental ...

China has recently approved the first locally developed obesity drug Xinermei (mazdutide), marking a critical milestone in the country’s obesity treatment landscape.

SHANGHAI, Aug. 2 (Xinhua) -- A landmark report on the global prevention and control of liver cancer, led by Chinese experts and recently published in The Lancet, presents a new international roadmap ...

WuXi XDC cited strong demand for antibody-drug conjugates, which are widely used in targeted cancer treatments, and for ...

In the first multinational study of a proposed change to how obesity is defined-which calls for health factors beyond a ...

Significant’ weight returned weeks after stopping drug, say researchers who advise patients to adjust expectations.

China is the second-most-popular country for obesity trials in recent years, behind the U.S. and ahead of Australia, STAT writes, citing a report from clinical research organization Novotech.

We look forward to filing for market approval in China as soon as possible to bring HRS9531 to patients struggling with obesity and overweight.” “We commend our colleagues at Hengrui for these ...

JIANGSU, China and WALTHAM, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera ...